Zealand Pharma reports wider loss for FY24, with lower revenues and higher expenses.

From Nasdaq: 2025-02-20 03:17:05

Zealand Pharma A/S reported a wider net loss for fiscal year 2024 due to lower revenues and higher operating expenses. The company’s net loss increased to 1.08 billion Danish Kroner from 703.74 million Danish Kroner in the previous year. Loss before tax also widened to 1.083 billion Kroner from 708.87 million Kroner. Operating expenses rose to 1.33 billion Kroner from 895.85 million Kroner. Revenues for the year fell to 62.69 million Kroner from 342.79 million Kroner the year before. For 2025, Zealand Pharma expects net operating expenses between 2.00 billion Kroner-2.50 billion Kroner.



Read more at Nasdaq: Zealand Pharma FY24 Loss Widens